Twenty one patients were enrolled, including 16 patients with NHL and 5 patients with B-ALL with measurable CD19+ R/R B-ALL or NHL disease after two or more prior treatment regimens. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.